Aging and Alzheimer's Disease: Lessons From the Nun Study
1997/04/01 by D. A. Snowdon, David A. Snowdon · 26 citations
Medicine · #Dementia and Cognitive Impairment Research #Frailty in Older Adults #Alzheimer's disease research and treatments
paper · doi:10.1093/geront/37.2.150
Abstract
Sister Mary, the gold standard for the Nun Study, was a remarkable woman who had high cognitive test scores before her death at 101 years of age. What is more remarkable is that she maintained this high status despite having abundant neurofibrillary tangles and senile plaques, the classic lesions of Alzheimer's disease. Findings from Sister Mary and all 678 participants in the Nun Study may provide unique clues about the etiology of aging and Alzheimer's disease, exemplify what is possible in old age, and show how the clinical expression of some diseases may be averted.
Citations
Cited by
- Scientific Truth or False Hope? Understanding Alzheimer's Disease from an Aging Perspective
- Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. [europepmc]
- Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. [europepmc]
- Healthy ageing in the Nun Study: definition and neuropathologic correlates. [europepmc]
- Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. [europepmc]
- NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. [europepmc]
- Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study. [europepmc]
- Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. [europepmc]
- Overview and findings from the religious orders study. [europepmc]
- Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. [europepmc]
- Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? [europepmc]
- Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology. [europepmc]
- p53-dependent SIRT6 expression protects Aβ42-induced DNA damage. [europepmc]
- Religious Orders Study and Rush Memory and Aging Project. [europepmc]
- Involvement of the Precuneus/Posterior Cingulate Cortex Is Significant for the Development of Alzheimer's Disease: A PET (THK5351, PiB) and Resting fMRI Study. [europepmc]
- Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. [europepmc]
- Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. [europepmc]
- A Literature Overview of Virtual Reality (VR) in Treatment of Psychiatric Disorders: Recent Advances and Limitations. [europepmc]
- Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. [europepmc]
- Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers? [europepmc]
- Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction. [europepmc]
- Evaluation of Speech-Based Digital Biomarkers: Review and Recommendations. [europepmc]
- Midlife lipid and glucose levels are associated with Alzheimer's disease. [europepmc]
- There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. [europepmc]
- Vascular contributions to Alzheimer's disease. [europepmc]
- The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking? [europepmc]
Related